Filing Details

Accession Number:
0001415889-24-000608
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-04 16:30:43
Reporting Period:
2024-01-02
Accepted Time:
2024-01-04 16:30:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1730430 Kiniksa Pharmaceuticals Ltd. KNSA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1464583 R Michael Megna C/O Kiniksa Pharmaceuticals, Ltd.
Clarendon House 2 Church Street
Hamilton D0 HM 11
Chief Accounting Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Share Acquisiton 2024-01-02 16,670 $13.88 33,675 No 4 M Direct
Class A Common Share Disposition 2024-01-02 16,670 $19.17 17,005 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Share Share Option Disposition 2024-01-02 16,670 $0.00 16,670 $13.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,014 2028-08-05 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
  2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.13 to $19.43. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  3. This option is fully vested and exercisable.